SG11201907276TA - Compositions of gallium (iii) complexes for oral administration - Google Patents

Compositions of gallium (iii) complexes for oral administration

Info

Publication number
SG11201907276TA
SG11201907276TA SG11201907276TA SG11201907276TA SG11201907276TA SG 11201907276T A SG11201907276T A SG 11201907276TA SG 11201907276T A SG11201907276T A SG 11201907276TA SG 11201907276T A SG11201907276T A SG 11201907276TA SG 11201907276T A SG11201907276T A SG 11201907276TA
Authority
SG
Singapore
Prior art keywords
international
gaq3
lexi
vancouver
pharma
Prior art date
Application number
SG11201907276TA
Other languages
English (en)
Inventor
Rickey Rhinebarger
Gina Stetsko
Original Assignee
Altum Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altum Pharmaceuticals Inc filed Critical Altum Pharmaceuticals Inc
Publication of SG11201907276TA publication Critical patent/SG11201907276TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
SG11201907276TA 2017-02-10 2018-02-09 Compositions of gallium (iii) complexes for oral administration SG11201907276TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762457712P 2017-02-10 2017-02-10
PCT/IB2018/000213 WO2018146551A2 (fr) 2017-02-10 2018-02-09 Compositions de complexes de gallium (iii) pour administration par voie orale

Publications (1)

Publication Number Publication Date
SG11201907276TA true SG11201907276TA (en) 2019-09-27

Family

ID=63106002

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201907276TA SG11201907276TA (en) 2017-02-10 2018-02-09 Compositions of gallium (iii) complexes for oral administration

Country Status (15)

Country Link
US (2) US10548849B2 (fr)
EP (1) EP3582778B1 (fr)
JP (1) JP2020513030A (fr)
KR (1) KR20190121784A (fr)
CN (1) CN110381945A (fr)
AU (1) AU2018218326A1 (fr)
BR (1) BR112019016400A2 (fr)
CA (1) CA3051545A1 (fr)
IL (1) IL268379A (fr)
MX (1) MX2019009510A (fr)
MY (1) MY194485A (fr)
PH (1) PH12019501868A1 (fr)
RU (1) RU2019128191A (fr)
SG (1) SG11201907276TA (fr)
WO (1) WO2018146551A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112118830B (zh) * 2018-05-14 2023-11-10 比利时胶囊公司 高活性剂载量的固体剂型

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004951A (en) * 1989-11-22 1999-12-21 Bernstein; Lawrence Richard Administration of gallium complexes of 3-hydroxy-4-pyrones to provide physiologically active gallium levels in a mammalian individual
WO2005058331A1 (fr) * 2003-12-17 2005-06-30 Titan Pharmaceuticals, Inc. Utilisation de gallium pour le traitement de l'arthrite inflammatoire
WO2007100382A2 (fr) * 2005-10-27 2007-09-07 Bernstein Lawrence R Préparations de gallium administrables per os et leurs méthodes d'utilisation
EA200801261A1 (ru) * 2005-11-04 2008-08-29 Джента Инкорпорейтед Фармацевтические композиции на основе галлия и способы
PE20081506A1 (es) * 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
KR101783676B1 (ko) 2010-02-12 2017-10-10 니키 파머 액퀴지션 코포레이션 2 혈액암의 치료 방법
CN102946880A (zh) 2010-04-23 2013-02-27 尼基制药公司 治疗胰腺癌的方法
US20140127271A1 (en) * 2012-04-11 2014-05-08 Intezyne Technologies, Inc. Block copolymers for stable micelles
TWI615157B (zh) * 2013-02-06 2018-02-21 大塚製藥股份有限公司 包括不定形西洛他唑的固體分散劑
CN105530918A (zh) * 2013-09-25 2016-04-27 陶氏环球技术有限责任公司 包含有机液体稀释剂和特定羟烷基甲基纤维素的组合物

Also Published As

Publication number Publication date
EP3582778A2 (fr) 2019-12-25
MY194485A (en) 2022-11-30
EP3582778A4 (fr) 2020-12-23
WO2018146551A2 (fr) 2018-08-16
PH12019501868A1 (en) 2020-07-06
CN110381945A (zh) 2019-10-25
US10933021B2 (en) 2021-03-02
AU2018218326A1 (en) 2019-08-22
WO2018146551A4 (fr) 2018-11-22
CA3051545A1 (fr) 2018-08-16
JP2020513030A (ja) 2020-04-30
BR112019016400A2 (pt) 2020-04-07
RU2019128191A3 (fr) 2021-05-31
KR20190121784A (ko) 2019-10-28
WO2018146551A3 (fr) 2018-10-04
RU2019128191A (ru) 2021-03-10
EP3582778B1 (fr) 2022-10-05
US10548849B2 (en) 2020-02-04
US20180228734A1 (en) 2018-08-16
US20200038334A1 (en) 2020-02-06
MX2019009510A (es) 2019-11-25
IL268379A (en) 2019-09-26

Similar Documents

Publication Publication Date Title
SG11201811432WA (en) Rna for cancer therapy
SG11201908813QA (en) Anti-sirp alpha antibodies
SG11201909949XA (en) Targeted immunotolerance
SG11201811442UA (en) Formulation of a peptide vaccine
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201907023UA (en) Method of reducing neutropenia
SG11201900844UA (en) Amino pyrimidine ssao inhibitors
SG11201908171TA (en) Compounds and compositions for treating hematological disorders
SG11201807809XA (en) A transient commensal microorganism for improving gut health
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201808686VA (en) Synthesis of indazoles
SG11201903076QA (en) Carbamoyl phenylalaninol compounds and uses therof
SG11201811559WA (en) Cancer treatment combinations
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201907420VA (en) Inhibition of smarca2 for treatment of cancer
SG11201806140SA (en) Stable liquid gonadotropin formulation